Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA LINC00319 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 22/March/2019, 8.23 am